17-Oct-2026 22:29:12
BAJAJHCAREGeneral news
BAJAJHCARE Q2 : STANDALONE NET PROFIT UP 26.9% AT 14.1 CR (YOY), UP 2.9% (QOQ). GOOD (On 1st Look)
Revenue up 18.9% at 175.9 Cr (YOY), up 6.2% (QOQ); H1 revenue up 15.1% at 341.5 Cr. Ebitda up 12.2% at 32.1 Cr (YOY), up 8.6% (QOQ); margins 18.2% v 19.3% (YOY), 17.8% (QOQ). Formulations revenue up 82% at 41.7 Cr (YOY); API exports up 28.5% at 62.6 Cr (YOY). First in India to get DCGI approval for Cenobamate API and tablets; long-term rating upgraded to IND A/Stable.
Bajaj Healthcare Limited
Open attachment